Article

Cheery News: Fibrofog Does Not Equal Creeping Dementia

ACR2013: Cognitive problems among fibromyalgia patients do not worsen over time or lead to anything resembling Alzheimer disease, a new study shows.

Reassuring news for your patients who have fibromyalgia: The condition may slow the brain somewhat, but the cognitive problems some patients call "fibrofog" do not represent the onset of gradually increasing dementia, according to new research from Rush University Medical Center in Chicago.  Nor do they resemble early Alzheimer disease.

Rheumatologist Robert Katz MD and psychologist Frank Leavitt PhD, who have been studying fibrofog for years, gave a battery of cognitive tests to patients who have fibromyalgia (documented according to the latest clinical criteria) and have noticed cognitive difficulties for either less than a year (69 subjects) or more than 7 years (39 subjects). With one minor exception, there was no significant difference between the groups, they report in an abstract for the American College of Rheumatology annual meeting. The exception was a test that incorporated a set of skills that are a subset of skills included in another test in which the two groups showed no significant difference.

Not only is continued cognitive decline not a feature of fibromyalgia, the deficits do not resemble early Alzheimer disease (as many patients with fibromyalgia fear).  Measures of episodic memory and processing speed, which are classic signs of preclinical Alzheimer disease, were in the normal range for both groups of subjects.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.